INC Research strengthens oncology team with two key appointments

Asli Turkes and Susan Timoney bring extensive expertise in clinical research and oncology
to the key therapeutic team

CAMBERLEY, UK, January 17, 2014 – INC Research, a global therapy-focused clinical research organization (CRO) with a trusted process^® for delivering reliable results, today announced the appointment of two senior executives to its oncology team. Dr. Asli Turkes has joined the Company as vice president of clinical development in oncology, and Dr. Susan Timoney has joined as executive director of clinical development in oncology. INC Research is organized around therapeutic business units to provide clients with specialized and experienced teams with leadership specifically tailored to ensure optimized strategy and a solid foundation for operational delivery, driven by therapeutics expertise. Dr. Turkes and Dr. Timoney’s extensive clinical research and specialized oncology expertise further strengthens INC Research’s world-class oncology business unit.

Dr Turkes will be based in INC Research’s Camberley office in the UK, while Dr Timoney will be based regionally in Scotland. They will support global research while adding specialized oncology leadership in Europe.

“I am delighted to add these two exceptionally talented individuals to our global oncology team,” said Dr. Nick Kenny, executive vice president and general manager of global oncology and hematology at INC Research. “Our oncology practice has experienced significant growth over the past year, so attracting the talent of this senior class is an important milestone. Dr. Turkes and Dr. Timoney have an impressive breadth and depth of understanding of clinical drug development from both the CRO and client perspective. perspectives will be invaluable in developing and executing the highest quality oncology trials for our clients around the world.”

Dr. Turkes brings over 30 years of clinical research experience, including 14 years in CRO where she served in the roles of Senior Project Manager, Project Director, Program Director, Senior Director of Oncology Drug Development and Senior Director of Customer Service. She led the development of a lead prostate cancer drug and an orphan drug for Gaucher disease from pre-clinical to NDA submission, and oversaw the program of two Phase III mega-trials in breast cancer for a monoclonal antibody drug. Her experience spans all phases of drug development from preclinical to Phase IV, NDA submissions and post-approval studies, and her therapeutic experience includes solid tumor indications in the treatment of prostate, breast, lung, ovary, melanoma, sarcoma and hematologic indications. oncology such as chemotherapy induced neutrocytopenia, NHL, mantle cell lymphoma, follicular lymphoma and CTC, ITP and leukemia. Dr. Turkes also has eight years of experience in academic research and teaching, as well as nearly a decade of experience in leadership positions.

Dr. Timoney is an experienced clinical research specialist with significant expertise in the implementation of projects in oncology (solid and hematological tumors), internal diseases, respiratory diseases, infectious diseases and CNS research. With over 18 years of experience in clinical trials, including 14 years of leading large global/international trials and programs, she was responsible for project management of global Phase I to IV trials, from program planning and launch through project closure and review. . For the past two years, Dr. Timoney has led an enterprise-wide strategic initiative to transform the way projects are delivered for a large CRO. Complementing his operational and project execution expertise, Dr. Timoney has significant management experience in executive positions, with responsibility for the overall management of European CRO operations. Dr. Timoney has also worked in the pharmaceutical sector, where she managed the clinical trials department of a specialty pharmaceutical company with primary interests in oncology, dermatology, infectious diseases and novel drug delivery mechanisms.

INC Research has conducted more than 600 Phase I to IV oncology trials involving nearly 39,000 patients at research sites around the world. The oncology team deals with a broad spectrum of solid cancers and hematological malignancies, including all types of drugs in development. The INC Research Oncology team is currently engaged in cutting-edge hematology-oncology clinical trials, several of which are likely to lead to changes in the standard of care in the near future. The team is focused on advancing scientific knowledge and helping patients through focused, thoughtful management of critical oncology research. For more information about INC Research’s oncology practice, click here. To read oncology case studies, click here.

About INC Research
INC Research is a therapeutic-focused clinical research organization with a strong reputation for conducting global clinical development programs with the highest integrity. Pharmaceutical and biotechnology companies turn to us for a full range of tailored Phase I to IV programs across all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic prediction lead customers to make more informed product development decisions, while our solid site relationships are a key success factor in delivering clinical trial results on time and on budget. INC was recognized as a “Top CRO” by sites worldwide in the CenterWatch Global Investigative Site Relationship Survey 2013. INC Research is headquartered in Raleigh, North Carolina. For more information, visit www.incresearch.com or follow us on the website @inc_research.

Contact: Bill Wherle, Media +1 (513) 763-1442

This announcement is being distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions customers.

The issuer of this advertisement guarantees that it is solely responsible for the content, truthfulness and originality of the information contained therein.
Source: INC RESEARCH, LLC via GlobeNewswire
Hug#1755489